URMC, FDA to collaborate on national data repository for hear...(neer Jean-Philippe Couderc Ph.D. the dir...),Health

Date:7/9/2008

neer Jean-Philippe Couderc, Ph.D., the director of the THEW project. "Current methods of measuring a drug's potential toxicity to the heart are insufficient. Scientists need access to more data so they can develop a better picture of what is going on in patients across time so we can do better measurements with more precision."

"The opportunity to interact with Dr. Couderc and the University of Rochester is important for at least two reasons," said Norman Stockbridge, M.D., director of FDA's Division of Cardiovascular and Renal Products. "First, they are accumulating unique data that will be useful in understanding how certain cardiac risks can be revealed by specific changes seen on the electrocardiogram. Second, Dr. Couderc and his colleagues bring valuable expertise in identifying properties of the ECG tracing that reveal whether a drug is causing a specific side effect, or that reveal a patient's susceptibility to dangerous heart arrhythmias."

Sudden cardiac arrest is the leading cause of death in the United States, resulting in over 450,000 deaths per year. One mechanism of cardiovascular death is related to drugs triggering a predisposition to lethal cardiac arrhythmias or by the drugs themselves. As part of FDA's regulatory review, the agency requires evidence of a drug's impact on the QT interval as one way to assess the cardiac risk associated with new compounds. The QT interval is a segment of an ECG recording that measures the process of ventricular repolarization the period between the heart's contraction and recovery phase. If a drug prolongs the repolarization process, then it is generally believed to heighten the risk for adverse cardiac events. Prolongation of the QT interval associated with episodes of fatal ventricular arrhythmias is a leading cause of removal of drugs from the market and was a leading impetus toward international collaboration to develop specialized studies to monitor the QT prolongation effects of new drugs
'/>"/>

Contact: Karin Christensen Karin_Christensen@urmc.rochester.edu 585-275-1311 University of Rochester Medical Center Source:Eurekalert

0 GOOD

Page: 1 2 3
Related medicine news :

1. Associates of Cape Cod (ACC) and MDS Analytical Technologies Collaborate to Offer a More Robust LAL Endotoxin Assay Platform
2. Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
3. Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R)
4. MedTrust Online Collaborates With Oracle and Dell to Provide Oncologists With the Next Generation Tool for Personalized Care Delivery
5. Endovascular Forum and CiDA Collaborate to Launch a Collective Intelligence Instrument for Dialysis Access Physicians
6. Mount Tabor Collaborates with Google Health
7. HHS, Cleveland Clinic Collaborate to Advance Treatment for Neurological Disorders
8. Leading HIV researchers to collaborate on vaccine development
9. The Feinstein to collaborate with Swedens Karolinska Institute
10. The Wistar Institute collaborates with the Coriell Institute to distribute cell lines
11. INCF and Allen Institute for Brain Science collaborate on Brain Atlas service improvement